Business
DKSH : Hong Kong and Hua Medicine strengthen Strategic Partnership to Advance Innovative Diabetes Solutions
DKSH : Hong Kong and Hua Medicine strengthen Strategic Partnership to Advance Innovative Diabetes
About this update from Dksh Holding Ltd
Back Share: RSS Feed Local & Trade News | Jun 29, 2026 DKSH Hong Kong and Hua Medicine strengthen Strategic Partnership to Advance Innovative Diabetes Solutions DKSH Hong Kong and Hua Medicine expand their strategic partnership, building on the successful delivery of the first Regulatory Affairs service in Macau, combining their respective strengths in innovative drug development and market expansion to accelerate the go-to-market and market introduction of pharmaceutical products for diabetes treatment in Hong Kong. This collaboration aims to enhance patient access to innovative diabetes therapies while creating long-term value for regional healthcare systems. Hong Kong, June 29, 2026 - DKSH, a leading market expansion services provider, today announced the expansion of its strategic collaboration with Hua Medicine Technology (Hong Kong) Limited, the wholly owned subsidiary of Hua Medicine, a pioneering pharmaceutical company dedicated to the research and development of innovative therapies for metabolic diseases. Building on the successful delivery of the first Regulatory Affairs service in Macau, this expanded partnership in Hong Kong combines both companies' strengths in innovative drug development and integrated market expansion capabilities. Through its Business Unit Healthcare, DKSH will provide comprehensive and core go-to-market and market access support for related products, continuously promoting regional healthcare accessibility and innovation. Under this expanded partnership, DKSH will provide comprehensive go-to-market support for Hua Medicine's products in the Hong Kong market. The partnership is designed to improve patient access to innovative treatments while creating long-term value for the regional healthcare ecosystem.With its integrated end-to-end platform, DKSH Healthcare will enable Hua Medicine to scale efficiently in Hong Kong. This will help accelerate product launch, market uptake and bring high-quality, innovative diabetes solutions to a broader patient population. Dr. Li Chen, Chief Executive Officer of Hua Medicine, said: "We are delighted to collaborate with DKSH. With its extensive experience in Hong Kong and the Greater Bay Area, strong market access and go-to-market capabilities, and robust distribution network, DKSH will help accelerate the market launch and adoption of our core product. This innovative therapy, whic...